171 related articles for article (PubMed ID: 36630951)
21. Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
Berndl F; Hassler MR
Curr Opin Urol; 2022 Jan; 32(1):48-53. PubMed ID: 34772864
[TBL] [Abstract][Full Text] [Related]
22. The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.
van Doeveren T; Nakauma-Gonzalez JA; Mason AS; van Leenders GJLH; Zuiverloon TCM; Zwarthoff EC; Meijssen IC; van der Made AC; van der Heijden AG; Hendricksen K; van Rhijn BWG; Voskuilen CS; van Riet J; Dinjens WNM; Dubbink HJ; van de Werken HJG; Boormans JL
Int J Cancer; 2021 Feb; 148(4):981-987. PubMed ID: 33006377
[TBL] [Abstract][Full Text] [Related]
23. Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma.
De Lorenzis E; Albo G; Longo F; Bebi C; Boeri L; Montanari E
Genes (Basel); 2021 Feb; 12(3):. PubMed ID: 33668859
[TBL] [Abstract][Full Text] [Related]
24. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
Yates DR; Catto JW
World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
26. Inherited Mutations in Women With Ovarian Carcinoma.
Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
[TBL] [Abstract][Full Text] [Related]
27. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.
Winters BR; De Sarkar N; Arora S; Bolouri H; Jana S; Vakar-Lopez F; Cheng HH; Schweizer MT; Yu EY; Grivas P; Lee JK; Kollath L; Holt SK; McFerrin L; Ha G; Nelson PS; Montgomery RB; Wright JL; Lam HM; Hsieh AC
JCI Insight; 2019 May; 5(13):. PubMed ID: 31145100
[TBL] [Abstract][Full Text] [Related]
28. Genomics in upper tract urothelial carcinoma.
Kammerer-Jacquet SF; Mathieu R; Peyronnet B; Rioux-Leclercq N; Bensalah K
Curr Opin Urol; 2017 Jan; 27(1):35-40. PubMed ID: 27584028
[TBL] [Abstract][Full Text] [Related]
29. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.
Carlo MI; Ravichandran V; Srinavasan P; Bandlamudi C; Kemel Y; Ceyhan-Birsoy O; Mukherjee S; Mandelker D; Chaim J; Knezevic A; Rana S; Fnu Z; Breen K; Arnold AG; Khurram A; Tkachuk K; Cipolla CK; Regazzi A; Hakimi AA; Al-Ahmadie H; Dalbagni G; Cadoo KA; Walsh MF; Teo MY; Funt SA; Coleman JA; Bochner BH; Iyer G; Solit DB; Stadler ZK; Zhang L; Rosenberg JE; Taylor BS; Robson ME; Berger MF; Vijai J; Bajorin DF; Offit K
J Clin Oncol; 2020 Feb; 38(5):406-414. PubMed ID: 31794323
[TBL] [Abstract][Full Text] [Related]
30. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors.
Lonati C; Necchi A; Gómez Rivas J; Afferi L; Laukhtina E; Martini A; Ventimiglia E; Colombo R; Gandaglia G; Salonia A; Briganti A; Montorsi F; Mattei A; Simeone C; Carlo MI; Shariat SF; Spiess PE; Moschini M;
Eur Urol Oncol; 2022 Feb; 5(1):30-41. PubMed ID: 34896051
[TBL] [Abstract][Full Text] [Related]
31. Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (hereditary nonpolyposis colorectal cancer syndrome).
Hubosky SG; Boman BM; Charles S; Bibbo M; Bagley DH
BJU Int; 2013 Oct; 112(6):813-9. PubMed ID: 23452166
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
[TBL] [Abstract][Full Text] [Related]
33. Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes.
Mossanen M; Nassar AH; Stokes SM; Martinez-Chanza N; Kumar V; Nuzzo PV; Kwiatkowski DJ; Garber JE; Curran C; Freeman D; Preston M; Mouw KW; Kibel A; Choueiri TK; Sonpavde G; Rana HQ
Clin Genitourin Cancer; 2022 Dec; 20(6):568-574. PubMed ID: 36127252
[TBL] [Abstract][Full Text] [Related]
34. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
35. Genomic profiling of Chinese patients with urothelial carcinoma.
Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China.
Yin L; Wei J; Lu Z; Huang S; Gao H; Chen J; Guo F; Tu M; Xiao B; Xi C; Zhang K; Li Q; Wu J; Gao W; Jiang K; Yu J; Miao Y
JAMA Netw Open; 2022 Feb; 5(2):e2148721. PubMed ID: 35171259
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study.
Dawood EE; Awadalla A; Hashem A; Shokeir AA; Abdel-Aziz AF
J Egypt Natl Canc Inst; 2022 Nov; 34(1):47. PubMed ID: 36372809
[TBL] [Abstract][Full Text] [Related]
39. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
40. Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis.
Na R; Wu Y; Jiang G; Yu H; Lin X; Wang M; Conran CA; Fantus RJ; Zhang N; Liu S; Helfand BT; Zheng SL; Isaacs WB; Ding Q; Shen Z; Xu J
BJU Int; 2018 Nov; 122(5):808-813. PubMed ID: 29727914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
